Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

Logo

SHANGHAI and HONG KONG, Oct. 8, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that it will release the latest preclinical results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) in a Poster Presentation at the 2026 American College of Rheumatology (ACR) Annual Meeting, taking place from November 6th to November 11th in Orlando, Florida, the United States. ATG-207 is our proprietary, globally first-in-class αCD3-TGF-β bifunctional fusion protein being developed for the treatment of T cell–mediated autoimmune diseases.

Logo

Recommended for you